2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.14A.02 Prognostic Factors in Malignant Pleural Mesothelioma Patients Receiving First-Line Chemotherapy: A Baseline Risk Score

EP.14A.02 Prognostic Factors in Malignant Pleural Mesothelioma Patients Receiving First-Line Chemotherapy: A Baseline Risk Score

Back to course

Pdf Summary

The study titled "Prognostic Factors in Malignant Pleural Mesothelioma Patients Receiving First-Line Chemotherapy: A Baseline Risk Score" aimed to develop and validate a new prognostic scoring system, the PLECH score, specifically for Latin American patients. This retrospective study was conducted at Mexico's National Cancer Institute and the National Medical Center, covering data from 2010 to 2023.<br /><br />The researchers focused on creating a straightforward and accessible prognostic tool due to the limitations of existing scores such as EORTC and CALGB, which are complex and often not adaptable to non-Hispanic populations. The team utilized univariate and multivariate analyses to identify key factors associated with overall survival (OS) and progression-free survival (PFS) in 262 patients with malignant pleural mesothelioma receiving first-line chemotherapy.<br /><br />The PLECH score includes five key variables derived from patient data: platelet count (P: 2 points), high LDH (L: 1 point), an ECOG performance status of 2 (E: 1 point), presence of chest pain at diagnosis (C: 2 points), and non-epithelioid histology (H: 1 point). These factors were statistically significant in predicting patient outcomes and were weighted according to their regression coefficients.<br /><br />The study found that patients categorized as high-risk by the PLECH score had significantly reduced median OS and PFS compared to those in the lower risk group, with OS of 12.3 months versus 20.1 months and PFS of 6.4 months versus 11.3 months, respectively. The PLECH score demonstrated better discriminatory ability (AUC = 0.70) than both the EORTC (AUC = 0.57) and CALGB (AUC = 0.60) scores.<br /><br />The authors suggest future research should focus on identifying alternative treatment strategies for high-risk patients and validate the PLECH score in prospective cohorts. The score's simplicity and use of widely available clinical variables make it a promising tool for prognostic assessment in malignant pleural mesothelioma.

Asset Subtitle

Alberto Guijosa

Meta Tag

Speaker Alberto Guijosa

Topic Mesothelioma, Thymoma, and Other Thoracic Tumors

Keywords

PLECH score

malignant pleural mesothelioma

prognostic factors

first-line chemotherapy

Latin American patients

National Cancer Institute

survival analysis

EORTC

CALGB

prognostic tool